Patient characteristics at enrollment
| Characteristic . | Total (%) (n = 35) . | A IBR 280 VEN 200 (n = 2) . | B IBR 420 VEN 200 (n = 16) . | C IBR 280 VEN 400 (n = 8) . | D IBR 560 VEN 200 (n = 4) . | E IBR 420 VEN 400 (n = 5) . |
|---|---|---|---|---|---|---|
| Mean age in years (min-max) | 63 (49-82) | 75 (69-82) | 62 (54-76) | 66 (49-79) | 62 (53-68) | 56 (50-60) |
| % male | 29 (83%) | 2 (100%) | 14 (87%) | 6 (75%) | 3 (75%) | 4 (80%) |
| Prior auto transplant (yes), % | 15 (43%) | 0 (0%) | 8 (50%) | 4 (50%) | 1 (25%) | 2 (40%) |
| Refractory to last line of therapy (yes), % | 18 (51%) | 2 (100%) | 5 (31%) | 4 (50%) | 3 (75%) | 4 (80%) |
| Lines of prior Rx | ||||||
| 1 line | 20 (57%) | 1 (50%) | 12 (75%) | 3 (38%) | 3 (75%) | 1 (20%) |
| 2 lines | 13 (37%) | 1 (50%) | 4 (25%) | 3 (38%) | 1 (25%) | 4 (80%) |
| 3 lines | 2 (6%) | 0 (0%) | 0 (0%) | 2 (25%) | 0 (0%) | 0 (0%) |
| Stage at enrollment | ||||||
| 1-2 | 2 (6%) | 0 (0%) | 1 (6%) | 0 (0%) | 1 (25%) | 0 (0%) |
| 3 | 6 (17%) | 1 (50%) | 2 (13%) | 1 (13%) | 1 (25%) | 1 (20%) |
| 4 | 27 (77%) | 1 (50%) | 13 (81%) | 7 (88%) | 2 (50%) | 4 (80%) |
| MIPI at enrollment | ||||||
| Low | 17 (49%) | 1 (50%) | 9 (56%) | 2 (25%) | 2 (50%) | 3 (60%) |
| Intermediate | 12 (34%) | 1 (50%) | 5 (31%) | 2 (25%) | 2 (50%) | 2 (40%) |
| High | 6 (17%) | 0 (0%) | 2 (13%) | 4 (50%) | 0 (0%) | 0 (0%) |
| Characteristic . | Total (%) (n = 35) . | A IBR 280 VEN 200 (n = 2) . | B IBR 420 VEN 200 (n = 16) . | C IBR 280 VEN 400 (n = 8) . | D IBR 560 VEN 200 (n = 4) . | E IBR 420 VEN 400 (n = 5) . |
|---|---|---|---|---|---|---|
| Mean age in years (min-max) | 63 (49-82) | 75 (69-82) | 62 (54-76) | 66 (49-79) | 62 (53-68) | 56 (50-60) |
| % male | 29 (83%) | 2 (100%) | 14 (87%) | 6 (75%) | 3 (75%) | 4 (80%) |
| Prior auto transplant (yes), % | 15 (43%) | 0 (0%) | 8 (50%) | 4 (50%) | 1 (25%) | 2 (40%) |
| Refractory to last line of therapy (yes), % | 18 (51%) | 2 (100%) | 5 (31%) | 4 (50%) | 3 (75%) | 4 (80%) |
| Lines of prior Rx | ||||||
| 1 line | 20 (57%) | 1 (50%) | 12 (75%) | 3 (38%) | 3 (75%) | 1 (20%) |
| 2 lines | 13 (37%) | 1 (50%) | 4 (25%) | 3 (38%) | 1 (25%) | 4 (80%) |
| 3 lines | 2 (6%) | 0 (0%) | 0 (0%) | 2 (25%) | 0 (0%) | 0 (0%) |
| Stage at enrollment | ||||||
| 1-2 | 2 (6%) | 0 (0%) | 1 (6%) | 0 (0%) | 1 (25%) | 0 (0%) |
| 3 | 6 (17%) | 1 (50%) | 2 (13%) | 1 (13%) | 1 (25%) | 1 (20%) |
| 4 | 27 (77%) | 1 (50%) | 13 (81%) | 7 (88%) | 2 (50%) | 4 (80%) |
| MIPI at enrollment | ||||||
| Low | 17 (49%) | 1 (50%) | 9 (56%) | 2 (25%) | 2 (50%) | 3 (60%) |
| Intermediate | 12 (34%) | 1 (50%) | 5 (31%) | 2 (25%) | 2 (50%) | 2 (40%) |
| High | 6 (17%) | 0 (0%) | 2 (13%) | 4 (50%) | 0 (0%) | 0 (0%) |